Man & Science names Prof. Jean-Pierre Van Buyten chief medical officer

By AI, Created 10:07 AM UTC, May 20, 2026, /AGP/ – Man & Science SA appointed neuromodulation expert Prof. Jean-Pierre Van Buyten as chief medical officer on May 7, 2026, as the Belgium-based device company advances its occipital nerve stimulation pilot and injectable peripheral nerve stimulation platform. The move adds a veteran pain-medicine leader to guide clinical strategy for programs aimed at refractory headache disorders and other neurological conditions.

Why it matters: - Man & Science is adding a senior neuromodulation specialist as the company tries to move clinical programs forward in headache and pain disorders. - Prof. Jean-Pierre Van Buyten will help shape the clinical strategy for both the occipital nerve stimulation pilot and the next-generation injectable peripheral nerve stimulation platform. - The appointment strengthens leadership around technologies aimed at minimally invasive treatment options for patients with severe and refractory headache conditions.

What happened: - Man & Science SA announced on May 7, 2026 that Prof. Jean-Pierre Van Buyten has been appointed chief medical officer. - The company is headquartered in Liège, Belgium. - Van Buyten has long been involved with Man & Science and now takes on the formal role of chief medical officer. - Hugues Wallemacq, CEO of Man & Science, said Van Buyten’s scientific credibility, clinical expertise and strategic insight will be important as the company advances its clinical programs.

The details: - Van Buyten has more than 80 peer-reviewed publications and more than 4,900 citations. - He has led the Multidisciplinary Pain Management Centre at VITAZ Hospital in Sint-Niklaas, Belgium since 2004. - His clinical focus has included spinal cord stimulation, peripheral nerve stimulation and neurostimulation for refractory headache and facial pain. - Van Buyten helped shape Man & Science’s scientific foundation and long-term clinical vision from the company’s early days. - He is a founding member of the Benelux Chapter of the International Neuromodulation Society. - He chairs the board of the European Continuing Medical Training, a nonprofit that coordinates more than 40 annual meetings and workshops across the EU on neuromodulation education. - His conference work has often focused on neurostimulation for head and facial pain, the target indication for Man & Science’s ONS program. - Man & Science’s lead programs include an occipital nerve stimulation program for refractory headache disorders and a proprietary injectable peripheral nerve stimulation platform designed to simplify implantation and broaden patient access. - The company described the injectable platform as next-generation and minimally invasive. - The company’s announcement included a LinkedIn page: company profile

Between the lines: - The appointment formalizes a relationship that already existed, which can shorten the path from research planning to clinical execution. - Bringing in a recognized pain-medicine figure may also help with credibility as Man & Science seeks to develop therapies in a niche neuromodulation market with high clinical and regulatory hurdles. - Van Buyten’s background in headache and facial pain aligns closely with the company’s lead indication, which suggests a tighter match between medical leadership and product strategy.

What’s next: - Van Buyten will lead clinical strategy and development as Man & Science continues its ONS clinical pilot study. - The company will keep advancing its injectable PNS platform alongside the ONS program. - Man & Science and its leadership say the goal is to accelerate next-generation therapies for patients with severe headache disorders.

The bottom line: - Man & Science is betting that a globally recognized neuromodulation expert can help turn two early-stage programs into more credible clinical and commercial opportunities.